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tions,” citing the rarity of home HD in the United States that is accumulated after the time of entry into the study
[3]. Causal mechanisms flow forward in time from theand Japan. It should be pointed out that out-center HD is
still common in Australia and New Zealand, and excellent perspective of the patient. Future information, which has
not been observed at the time of entry into a study, shoulddata are available through the Australia and New Zealand
Transplant (ANZDATA) Registry [2]. Currently, 43% of not be used to predict risk of future events. An added
complexity in examining the blood pressure–allograft sur-HD patients in New Zealand dialyze at home and 3% in
satellite units, while in Australia the figures are 18% and vival relationship is that elevated BP may not only cause,
but may result from decreased allograft function. Ad-41%, respectively [2]. Our dialysis unit, which was estab-
lished in 1969 and serves a population of 480,000, offers justing for renal function at the time the BP reading is
obtained is appropriate to examine the relationship, inde-only home dialysis. We recently published our 30-year
experience [3] reporting a median survival of 7.75 years pendent of renal function, of BP and allograft failure at
or after that point in time. BP measurements taken at thefor home HD patients who were less selected because no
in-center HD program existed. This patient survival was time when the allograft is failing will tend to be higher
because of worsened renal function. Constructing a “base-superior to hospital HD elsewhere in this region. The
quality of life, survival and cost benefits of home HD that line” covariate derived from later BP readings taken when
the allograft is failing will bias the conclusion about thewere recognized in the 1960s still apply today, a fact not
forgotten here. Geographical isolation, with many patients BP-allograft survival relationship. In regression analyses,
the use of events that occur after the time of entry intoliving in isolated rural areas, and an absence of financial
disincentives to prescribing home HD are other reasons a study to predict future events can lead to illogical results
such as their finding that there was an increased risk offor its continued use. Our experience, which is similar to
that of Arkouche et al, suggests that this very successful allograft failure with increasing average time of follow-
up. Allografts that have better survival have longer follow-technique should be utilized more in other parts of the
world. up times.
David O. McGregor, Adrian L. Buttimore, and Kelvin L. Lynn Kevin Mange and Harold Feldman
Department of Nephrology, Christchurch Hospital, Christchurch, Philadelphia, Pennsylvania, USA
New Zealand
Correspondence to Kevin Mange, M.D., University of Pennsylvania
Correspondence to Dr. David McGregor, Department of Nephrology, Health System, Department of Medicine, 700 Clinical Research Building,
Christchurch Hospital, Private Bag 4710, Christchurch, New Zealand. 415 Curie Boulevard, Philadelphia, Pennsylvania 19104-6144, USA
E-mail: davidm2@chhlth.govt.nz
REFERENCES
REFERENCES
1. Cosio FG, Pelletier RP, Sedmark DD, Pesavento TE, Henry ML,
1. Arkouche W, Traeger J, Delawari E, Sibai¨-Galland R, Abdul- Ferguson RM: Renal allograft survival following acute rejection
lah E, Galland R, Leitienne P, Fouque D, Laville M: Twenty- correlates with blood pressure levels and histopathology. Kidney Int
five years of experience with out-center hemodialysis. Kidney Int 56:1912–1919, 1999
56:2269–2275, 1999 2. Mange KC, Cizman BC, Joffe M, Feldman HI: Arterial Hyperten-
2. ANZDATA Registry Report 1998. Adelaide, South Australia, Aus- sion and Renal Allograft Survival. JAMA (in press)
tralia and New Zealand Dialysis and Transplant Registry, edited by 3. Wolfe RA, Strawderman RL: Logical and statistical fallacies in the
Disney APS, Russ GR, Walker R, Collins JF, Herbert K, Kerr use of Cox regression models. Am J Kidney Dis 27:124–129, 1996
PG, 1998
3. McGregor DO, Buttimore AL, Robson RA, Little PJ, Morton
JB, Lynn KL: Thirty years of universal home dialysis in Christchurch.
NZ Med J 113:27–29, 2000
Lowering C-peptide levels and
renoprotective therapy
Blood pressure and prediction To the Editor: In a recent editorial by Hebert on reno-
protective therapy, one of the proposed strategies con-of patient outcome
sisted of lowering C-peptide levels, based on animal evi-
dence and human epidemiological data that elevatedTo the Editor: We were initially encouraged by the
recent publication of Cosio et al [1] that supported our insulin levels promote glomerulosclerosis [1]. Exercise,
weight reduction, and diet low in refined sugars were firststudy that demonstrated an increased rate of allograft
failure with increasing levels of blood pressure (BP) [2]. mentioned to lower C-peptide levels “when these patients
develop renal disease” [1]. However, if that proves unsuc-Upon further review, we have concerns about the use of
BP data during follow-up as if they were baseline charac- cessful, a pharmacological approach, which provides some
concerns, was suggested.teristics. In survival analysis, it is improper to use as a
baseline predictor, covariates constructed on information Dimethylbiguanide (metformin) is proposed as an ap-
